Promising Outlook for Disc Medicine: Buy Rating Backed by FDA Priority Voucher and Strategic Preparations for Bitopertin Launch
I'm PortAI, I can summarize articles.
Douglas Tsao has issued a Buy rating for Disc Medicine, citing the promising outlook for its drug candidate, bitopertin, which has received the FDA's Commissioner’s National Priority Voucher, expediting its review process. The drug also holds Orphan Drug and Rare Pediatric Disease Designations. Disc Medicine is preparing for a commercial launch with a fully staffed team and a managed supply chain. Tsao's price target is $118, while Morgan Stanley also maintains a Buy rating with a $90 target, despite some regulatory and financial risks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments